{"entity":{"id":"nct07227025","kind":"trial","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Amivantamab and Olomorasib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07227025 by Janssen Research & Development, LLC, with 60 participants planned, started 2026-03-03 and due to reach its primary completion in 2028-11-30. Interventions recorded: Amivantamab and Olomorasib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07227025","url":"https://clinicaltrials.gov/study/NCT07227025"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["amivantamab","olomorasib"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07227025","phase":"1/2","setting":"A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","enrolled":60,"outcomes":[]},"route":"/trials/nct07227025/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"olomorasib","kind":"drug","name":"Olomorasib","route":"/drugs/olomorasib/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}